Psyber Inc

Psyber Inc is a Toronto-based digital mental health company developing AI-powered tools designed to personalize and enhance psychedelic-assisted therapy sessions. Their platform leverages advanced biometric and psychological state tracking to provide therapists with real-time insights into patient responses during treatment. By combining machine learning algorithms with clinical data, Psyber enables more precise dosing, therapy timing, and intervention strategies tailored to individual patient needs. The technology bridges the gap between the emerging psychedelic medicine space and modern digital health infrastructure.

Having secured $4M in seed funding, Psyber is positioned at the forefront of the intersection between psychedelic medicine and digital therapeutics. The company's platform addresses a critical gap in clinical practice where therapists currently lack objective data to guide their treatment decisions during psychedelic sessions. This innovation comes at a pivotal moment when regulatory pathways for psychedelic-assisted therapies are expanding globally, creating significant demand for standardized, monitored treatment protocols. Psyber's tools are helping establish the clinical infrastructure needed to scale these therapies responsibly and effectively.

Psyber represents an important convergence in neurotech where AI, biometric monitoring, and emerging psychiatric treatments create new possibilities for mental health care. The company's work is significant because it addresses treatment-resistant conditions like depression and PTSD by making psychedelic therapies safer, more reproducible, and accessible through better monitoring and personalization. By providing therapists with objective data during sessions, Psyber is helping legitimize psychedelic medicine within mainstream healthcare systems. Their platform exemplifies how neurotechnology can accelerate the clinical validation and wider adoption of promising but underutilized therapeutic approaches.